What's in Universidad Nacional de Colombia's pipeline?

Universidad Nacional de Colombia has 5 drugs in our index: 0 marketed, 0 filed, 3 in Phase 3, 0 in Phase 2, 2 in Phase 1.

Which companies overlap with Universidad Nacional de Colombia's portfolio?

Top competitors by shared drug class: Allergan, Assistance Publique - Hôpitaux de Paris, Bausch & Lomb Incorporated, Massachusetts Eye and Ear Infirmary, National University of Malaysia.

How do I subscribe to ongoing alerts?

Subscribe to /feed/company/universidad-nacional-de-colombia.xml in any RSS reader. Every regulatory action and pipeline update lands in your feed.

Last reviewed 2026-05-17 · How we verify

Universidad Nacional de Colombia — Portfolio Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Universidad Nacional de Colombia pipeline: 0 marketed, 0 filed, 3 Phase 3, 0 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

0 marketed 0 filed 3 Phase 3 0 Phase 2 2 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

Drug	Generic	Phase	Class	Target	Area
Ivermectin 0.1% Metronidazole 1%	Ivermectin 0.1% Metronidazole 1%	phase 3	Antiparasitic/Antimicrobial combination	Glutamate-gated chloride channels (ivermectin); DNA/anaerobic metabolism (metronidazole)	Infectious Disease / Dermatology
Fluconazole and Secnidazole	Fluconazole and Secnidazole	phase 3	Antifungal/antiprotozoal combination	Fungal CYP51 (lanosterol 14α-demethylase); protozoal DNA	Infectious Disease
Standard care Hyaluronic acid eye drops	Standard care Hyaluronic acid eye drops	phase 3	Ophthalmic lubricant		Ophthalmology

Therapeutic area mix

Infectious Disease · 1
Infectious Disease / Dermatology · 1
Ophthalmology · 1

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

Allergan · 1 shared drug class
Assistance Publique - Hôpitaux de Paris · 1 shared drug class
Bausch & Lomb Incorporated · 1 shared drug class
Massachusetts Eye and Ear Infirmary · 1 shared drug class
National University of Malaysia · 1 shared drug class
Nguyen Viet Giap · 1 shared drug class
Ophthalmic Consultants of Long Island · 1 shared drug class
Tianjin Medical University Eye Hospital · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Universidad Nacional de Colombia:

Cite this brief

Drug Landscape (2026). Universidad Nacional de Colombia — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/universidad-nacional-de-colombia. Accessed 2026-05-17.